Summary & Overview
HCPCS G9896: Documentation for Omission of ADT with Prostate External Beam Radiotherapy
HCPCS Level II code G9896 records documentation of patient-specific reasons for not prescribing or administering androgen deprivation therapy (ADT) when external beam radiotherapy is delivered to the prostate. The code supports capture of clinical decision-making where combined-modality therapy was considered but omitted, enabling clearer audit trails and supporting quality measurement around prostate cancer treatment planning. Nationally, standardized use of G9896 can improve clarity in claims and clinical records, inform quality reporting, and reduce ambiguity in payer review of prostate radiotherapy episodes.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code's clinical purpose, common settings where it applies, payer coverage considerations, and typical documentation expectations. The publication outlines benchmarks and policy implications relevant to billing and quality reporting, highlights where documentation is commonly required, and summarizes how G9896 interacts with radiation oncology workflows. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9896 documents the patient reason(s) for not prescribing or administering androgen deprivation therapy (ADT) in combination with external beam radiotherapy to the prostate. This code captures clinical documentation when ADT is considered but not used alongside prostate external beam radiotherapy.
Service Type: Clinical documentation / Decision-support related to cancer treatment planning
Typical Site of Service: Radiation oncology clinic or hospital outpatient radiation therapy department
Clinical & Coding Specifications
Clinical Context
A 72-year-old male with newly diagnosed intermediate- to high-risk localized prostate adenocarcinoma is referred to radiation oncology for consideration of definitive external beam radiotherapy (EBRT). The multidisciplinary team discusses combining EBRT with androgen deprivation therapy (ADT) to improve oncologic outcomes. During the consultation, the patient reports severe baseline erectile dysfunction, significant cardiovascular comorbidity (recent myocardial infarction within 6 months), and strong refusal of hormonal therapy due to prior adverse effects. The radiation oncologist documents a detailed discussion of the risks and benefits of ADT, alternative options, and the patient’s reasons for declining ADT. The documentation specifically records medical contraindications, prior adverse reactions, patient preference, and the planned EBRT regimen without concurrent ADT.
Typical clinical workflow:
-
The urologist and radiation oncologist review staging, PSA, Gleason score, and cardiac history.
-
The radiation oncologist conducts an informed consent discussion that includes the role of ADT with EBRT, documents the rationale for not prescribing ADT, and notes any shared decision-making and informed refusal.
-
The clinical note is coded with the HCPCS Level II code
G9896to indicate documentation of reasons for not prescribing/administering ADT in combination with EBRT to the prostate. -
Radiation treatment planning and delivery proceed according to the documented plan without concurrent ADT, and relevant progress notes and treatment summaries reference the prior documentation.